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se of Ultrasound Contrast Agents for
ene or Drug Delivery in Cardiovascular Medicine
affi Bekeredjian, MD,* Paul A. Grayburn, MD, FACC,† Ralph V. Shohet, MD*
allas, Texas
The clinical utility of ultrasound contrast agents has been established in diagnostic
echocardiography. Recently, the use of such agents has been promoted for transport and
delivery of various bioactive substances, thus providing a technique for non-invasive gene
therapy and organ-specific drug delivery. In this review, we give a critical update of published
studies using ultrasound contrast agents for therapeutic use. We discuss the potential
applications and limitations of this technique and suggest future applications in cardiovascular
medicine. (J Am Coll Cardiol 2005;45:329–35) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.08.067Cardiology Foundation
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wltrasound contrast agents have been used in diagnostic
chocardiography for several decades. The development of
ewer, second-generation contrast agents that cross the
ulmonary circulation has enabled the opacification of the
eft ventricular cavity and myocardium after intravenous
njection (1–3). An important physical characteristic of such
gents is that they oscillate during sonication. These oscil-
ations can result in linear backscatter at low acoustic
ressure, nonlinear signals with harmonic frequencies at
edium acoustic pressure, and microbubble disintegration
t high acoustic pressure (4). The destruction of micro-
ubbles has been used in myocardial contrast echocardiog-
aphy (MCE) to quantitate myocardial microperfusion us-
ng refill kinetics (5,6). Briefly, a high-power ultrasound
ulse is used to destroy the microbubbles within the
yocardial capillary bed, and then low-power ultrasound is
sed to measure the time course of replenishment of the
apillary bed with microbubbles. Microbubble destruction
y ultrasound has also raised questions about bioeffects in
he vicinity of contrast agents. Early studies showed capil-
ary rupture and local extravasation of red blood cells in
keletal muscle (7–9) after ultrasound-targeted microbubble
estruction (UTMD). Although this phenomenon indi-
ated that microbubble destruction can induce adverse
ffects, these bioeffects were seen only at much higher doses
f microbubbles than are used clinically, as well as at local
ltrasound pressures higher than would be expected in
linical imaging. Importantly, these studies demonstrated
he potential for delivery of bioactive substances to
ltrasound-accessible organs.
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ccepted August 17, 2004.In recent years, several investigators have used ultrasound
ontrast agents as a tool for organ-specific drug and gene
elivery. In this review, we give an overview of these studies
nd analyze the different strategies that have been used.
fter introducing the mechanical and chemical concepts of
ubstance delivery with ultrasound contrast agents, we
escribe studies that have examined the use of UTMD for
ene therapy, drug delivery, and direct mechanical bioef-
ects. Finally, we discuss potential risks of microbubble
estruction and suggest future applications.
RANSPORT OF SUBSTANCES BY
LTRASOUND CONTRAST AGENTS
ost investigators who have used ultrasound contrast
gents for therapeutic applications work with perfluorocar-
on bubbles stabilized by an albumin or lipid shell. The
dvantages of this class of contrast agents include their
ragility when exposed to moderate energy ultrasound and
heir ease of manufacture. Three concepts have been de-
cribed: 1) microbubbles can be produced together with a
ioactive substance, thus potentially incorporating it into
he microbubble shell or lumen (10–13); 2) microbubbles
an be incubated with a bioactive substance, thus attaching
he substance to the microbubble shell, presumably by
lectrostatic or weak non-covalent interactions (14–16); or
) microbubbles and the bioactive substance can be co-
dministered (8,9,17). Several considerations affect the
hoice of how to combine the microbubble and its bioactive
omponent.
It is well known that deoxyribonucleic acid (DNA) is
apidly degraded after injection into the bloodstream by
erum DNases (18) and removed by hepatic scavenger
eceptors (19). Thus, intravenous injection of plasmid
NA, even in the presence of ultrasound, does not lead to
etectable transfection. Unpublished data from our own
aboratory show that plasmid DNA that is incorporated
ithin the microbubble shell (confirmed by fluorescent
icroscopy) is not significantly degraded by exposure to
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Gene Therapy Using Contrast Echocardiography February 1, 2005:329–35uman whole blood. Therefore, it appears that DNA is
rotected from serum DNases if it is either attached to
icrobubbles or, preferably, integrated into the micro-
ubble shell. However, the exact mechanisms of protection
ave not been elucidated.
Transport of a substance by microbubbles requires chem-
cal compatibility with the microbubble shell. The most
ommon component of microbubbles—albumin—can bind
wide range of substances, such as drugs, DNA, and virus
articles (20). Cationic lipids have the advantage of binding
egatively charged DNA. Thus, the use of such lipids in
icrobubbles has been promoted for DNA delivery (21,22).
Depending on the thermal stability of the therapeutic
ubstance, sonication as a method to produce microbubbles
ay not be feasible, as temperatures reach more than 70°C.
herefore, the transport of a heat-labile virus or proteins
equires either passive attachment to preformed bubbles
10,11) or lipid microbubble production by shaking (23). It
s also important that sonication should not mechanically
isrupt a substance. Integrity of plasmid DNA after soni-
ation in an albumin solution has been shown to be
naltered (11).
A few studies have used ultrasound contrast agents that
re not based on microbubbles, such as gas-filled poly(D,L-
actide-co-glycolide) microparticles produced with DNA/
olymer complexes (24) or echogenic liposomes that are
ehydrated, lyophilized, and then re-hydrated with a drug
olution (25). However, ultrasound contrast agents that are
ot filled with gas cannot take advantage of important
hysical characteristics, such as oscillations, microstreaming,
nd microbubble disruption.
Advances in the chemistry of microbubble formulation
ould improve both the stability of the bubbles and their
inding capacity for gene or drug delivery.
elivery of substances by microbubble destruction. The
oncept of delivering a bioactive substance by UTMD has
wo components. First, the transported substance can be
eleased from the microbubbles by their destruction in the
arget region, thus increasing its local concentration. Sec-
nd, the destruction of the bubbles may cause focal cavita-
ion effects in the surrounding tissue that increase the
ermeability of biologic barriers (Fig. 1). This may be
articularly important when using UTMD for gene delivery
ith naked DNA, because transfection efficiency across cell
embranes would otherwise be very low.
Ultrasound alone has been shown to improve DNA
ptake (26,27), drug (28), and protein (16) delivery into
Abbreviations and Acronyms
DNA  deoxyribonucleic acid
GFP  green fluorescent protein
UTMD  ultrasound-targeted microbubble destruction
VEGF  vascular endothelial growth factorissues without microbubbles. There are several potential mechanisms that could play a role in mediating this effect. It
s known that ultrasound induces an oscillating convective
otion to partially absorbing liquids (29). This might
nhance diffusion of drugs or other substances in vivo. In
ddition, ultrasound heats tissue, which could theoretically
nhance drug delivery. Finally, ultrasound can directly
nduce gas bubble formation and destruction (30). This
rocess, known as cavitation, is associated with a number of
econdary effects, which will be discussed.
Several studies have investigated the mechanisms for how
TMD enhances DNA delivery into cells. Electron mi-
roscopy has demonstrated pore formation on cell mem-
ranes immediately after destruction of microbubbles; this
henomenon is transient, with disappearance of the pores
fter 24 h (31–33). Such “sonoporation” effects may help
acilitate gene or drug entry into the cell. In vitro studies on
ingle bubbles have shown that even linear bubble oscilla-
ions are sufficient to achieve rupture of lipid membranes
34). Moreover, sudden violent collapse of microbubbles
inertial cavitation) can produce high-velocity fluid micro-
ets that may penetrate adjacent membranes (35). In addi-
ion, inertial cavitation, which is dependent on microbubble
hell composition, ultrasound frequency, pulse duration, and
coustic power (36,37), can lead to secondary shock waves
38,39), transient local high temperatures (40), and shear
tress (41), all of which could potentially contribute to gene
r drug delivery by UTMD.
The disruption force of microbubbles is greater when the
ltrasound frequency used matches the resonant frequency
f microbubbles (36,42–44). Even low acoustic pressures
an result in microbubble destruction (44), but higher
ressures (around 2 Mpa) will lead to more forceful reac-
ions. A higher disruption force enhances delivery of a
ransported substance (42). Several studies have investigated
arious ultrasound modalities to identify optimal settings for
ighest delivery efficiencies. In the myocardium, triggered
ltrasound has been shown to be superior to continuous
ltrasound (44,45), presumably because the latter destroys
igure 1. Schematic representation of substance delivery using ultrasound-
argeted microbubble destruction. An ultrasound contrast agent with an
ttached or incorporated bioactive substance is administered into the
asculature and will distribute throughout the capillaries. Ultrasound can
hen destroy microbubbles in the target region, thus releasing the trans-
orted substance into the surrounding tissue.ost of the microbubbles within the cardiac chambers and
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February 1, 2005:329–35 Gene Therapy Using Contrast Echocardiographyhe coronary arteries before they can reach the myocardial
apillaries. No difference was seen between the ultrahar-
onic and power Doppler mode (44). However, this was
nvestigated in small animal models that would show a very
ow level of ultrasound attenuation. In larger animals or
umans, differences between ultraharmonic and power
oppler could be present.
HERAPEUTIC CONCEPTS
hree delivery goals have been considered for UTMD. The
ost widely investigated application is for gene transfer/
ene therapy. A second application is for drug and protein
elivery. Finally, UTMD alone has been studied for thera-
eutic effects by itself (without any transported substance).
able 1 gives an overview of studies that have used ultra-
ound contrast agents to transport bioactive substances in
ivo. It is evident from Table 1 that more data are currently
vailable for delivery of genes rather than drugs or proteins.
ene transfer/gene therapy. Increased knowledge about
olecular mechanisms of diseases and physiologic regula-
ion has raised expectations for gene therapy as a new
reatment option. Despite substantial effort in cardiovascu-
ar medicine to develop and test gene therapy techniques,
one has yet progressed beyond clinical studies (46). Use of
TMD provides many desirable characteristics for gene
herapy, including low toxicity, low immunogenicity, low
nvasiveness, the potential for repeated application, organ
pecificity, and broad applicability to sonographically acces-
ible targets. The main strategies for delivering a gene
herapy vector by UTMD have been production of albumin
icrobubbles with DNA, production of neutrally charged
able 1. Chronologic Overview of Studies That Have Used Ultra
o Muscle or Vessels
Target Method Transported Substa
eart In vivo CMV-beta-galactosidase adenovirus
SMC, EC In vitro CMV-luciferase plasmid
eart In vivo Vascular endothelial growth factor p
eart In vivo Chloramphenicol acetyltransferase
SMC, EC, carotid In vitro
In vivo
CMV-luciferase and anti-oncogen (p
keletal muscle In vivo HGF plasmid
arotid Ex vivo Beta-galactosidase and eNOS plasmi
93 cells In vitro CMV-luciferase
ouse fetus In vivo Beta-galactosidase and GFP plasmid
eart In vivo CMV-luciferase adenovirus and plas
eart In vivo CMV-luciferase plasmid
eart In vivo Antisense oligonucleotide for TNF-a
oronary Ex vivo Antisense oligomer
keletal muscle In vivo CMV-luciferase
keletal muscle In vivo CMV-GFP
keletal muscle In vitro
In vivo
CMV-luciferase
hick embryo In vivo Beta-galactosidase, GFP, and Sonic
arotid In vivo Decoy oligodeoxynucleotides
eart In vivo Luciferase protein
MV  cytomegalovirus; EC  endothelial cell; GFP  green fluorescent protein
icrobubble; TNF-alpha  tumor necrosis factor-alpha; VSMC  vascular smoothr cationic lipid microbubbles with DNA or adenovirus, rncubation of albumin microbubbles with adenovirus, and,
ost widely applied, incubation of DNA with Optison (GE
ealthcare, Milwaukee, Wisconsin). The amount of DNA
dministered by UTMD in these studies varied from as little
s 10 g to as much as 2 mg. This demonstrates that further
ose-finding studies with optimized microbubble composi-
ions are still needed. Three main targets have been inves-
igated: the myocardium, vessels, and skeletal muscle. The
ollowing section describes the most important in vivo, ex
ivo, and in vitro studies (Table 1) that have been performed
sing UTMD for gene transfer.
The first study using UTMD for cardiac gene delivery used
cytomegalovirus beta-galactosidase–expressing adenovirus
ttached to albumin microbubbles (10). Although a 10-fold
ugmentation of cardiac beta-galactosidase expression was
chieved in rats, adenoviral vectors have the disadvantage of
ow organ specificity (with a strong hepatic tropism) and
mmunogenicity that inhibits repeated applications. Subse-
uent studies extended this approach to the delivery of
lasmid DNA to rats using sensitive reporter constructs to
vercome the inefficiency that is the principal limitation of
his method (42,47). In contrast to an adenoviral approach,
he use of naked DNA resulted in a nearly 100% organ
pecificity, as DNA released into the circulation was rapidly
igested by serum DNases, thus not transfecting other
issues. The temporal expression profile was investigated,
howing highest transgene expression at day 4 after UTMD,
ith a rapid decline thereafter. Repeated treatments were
ble to prolong high-level luciferase expression (47). The
bility to repeat the application provides the opportunity to
ontrol the duration of transgene expression, an important
d-Targeted Microbubble Destruction for Delivery of Substances
Microbubble Study (Ref.)
Albumin MB Shohet et al. (10)
Optison Lawrie et al. (14)
Albumin MB Mukherjee et al. (16)
Cationic MB Vannan et al. (21)
lasmid Optison Taniyama et al. (49)
Optison Taniyama et al. (53)
Albumin MB Teupe et al. (51)
Albumin MB Frenkel et al. (11)
Optison Endoh et al. (55)
Albumin and lipid MB Chen et al. (44)
Albumin and lipid MB Bekeredjian et al. (47)
Albumin MB Erikson et al. (12)
Albumin MB Kipshidze et al. (48)
Cationic MB Christiansen et al. (22)
Optison Lu et al. (52)
Optison and Albumin MB Pislaru et al. (15)
ehog plasmid Optison Ohta et al. (54)
Optison Hashiya et al. (50)
Lipid MB Bekeredjian et al. (23)
S  endothelial nitric oxide synthase; HGF  hepatocyte growth factor; MB 
le cell.soun
nce
rotein
53) p
d
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Hedgequirement for gene therapy of acquired diseases. Other
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Gene Therapy Using Contrast Echocardiography February 1, 2005:329–35yocardial gene transfer studies have been commenced to
tudy biologically important treatment with antisense oli-
onucleotide delivery for tumor necrosis factor-alpha, re-
ulting in reduced tumor necrosis factor-alpha production
fter ischemia in rats (12). There have also been initial
fforts to scale this approach up to larger animals, using
eporter gene delivery to canine hearts (21).
Blood vessels (either vascular walls or endothelium) seem
o be obvious targets for microbubbles and ultrasound,
ecause they are the first tissue exposed to the microbubbles.
everal in vitro and in vivo studies have been performed to
valuate transfection and the physiologic response to
TMD in vessels. Cultured vascular smooth muscle cells
nd endothelial cells were transfected with plasmids and
ptison, showing 3,000-fold higher expression than ob-
ained with naked DNA alone (14). Porcine coronary
rteries (ex vivo) could be transfected with antisense phos-
horodiamidate morpholino oligomers, resulting in modest
nhibition of c-myc, with the goal of reducing intimal
roliferation (48). Rat carotid arteries were transfected with
nti-oncogene (p53) plasmids and Optison after balloon
njury, resulting in a significant reduction of intimal prolif-
ration (49). Similarly, decoy oligodeoxynucleotides were
sed with Optison to reduce intimal proliferation in
alloon-injured rat carotids (50). The transfection of endo-
helial nitric oxide synthase expression vectors to porcine
arotids (ex vivo) resulted in detectable endothelial nitric
xide synthase expression and a blunted contractile response
o prostaglandin (51).
Studies of UTMD in skeletal muscle are pertinent to
ardiovascular treatment because of the similarity of cardiac
nd skeletal muscle as target tissues. Two different strategies
ave been described to transfect skeletal muscle. Direct
njection of Optison and green fluorescent protein (GFP)
ncoding plasmids into the skeletal muscle with ultrasound
pplication increased GFP expression compared with intra-
uscular naked plasmid injection alone and, at the same
ime, reduced muscle damage (in vivo) (52). This study also
emonstrated an enhanced transfection of DNA by micro-
ubbles alone (without ultrasound), although the mecha-
ism for this finding was not elucidated. In a second
pproach, intravascular infusion of cytomegalovirus-
uciferase encoding plasmids bound to cationic micro-
ubbles with ultrasound was able to achieve luciferase
xpression in rat skeletal muscle, with intra-arterial appli-
ation more efficient than intravenous infusion (22).
aniyama et al. (53) demonstrated increased capillary den-
ity in rabbit skeletal muscle using hepatocyte growth factor
lasmid combined with Optison.
A few studies have even attempted to use UTMD to
erform embryonic or fetal transfections. Chick embryos
ere transfected with direct injection of Optison and
lasmids (beta-galactosidase, GFP, and the important de-
elopmental gene Sonic Hedgehog), together with ultra-
ound application (54). Reporter gene expression was iden-
ified and digit malformation was seen with Sonic tedgehog (54). Another study used UTMD for fetal gene
ransfer in mice. Optison and plasmids (beta-galactosidase
nd GFP) were injected either intra-amniotically or into the
eritoneum of the fetus. Gene expression in fetal tissues was
,000-fold higher compared with injection naked DNA
lone. Various organs could be transfected, including the
rain, lung, heart, gut, and skin (55). These studies dem-
nstrate the potential utility of this technique as a tool in
tudies of developmental biology.
Despite the promising results in gene transfer mediated
y UTMD, its major limitation has been low transfection
fficiency. Most studies have compared the gene expression
fter UTMD with application of naked plasmid DNA
lone. In many studies, transgene expression was substan-
ially higher (up to several 1,000-fold) compared with naked
lasmid administration. However, considering the generally
ow transfection efficiency with naked DNA alone, this
esult still does establish that gene transfer efficiency will
uffice for clinical applications. Several questions still have to
e addressed. How many cells can be transfected in an
rgan? Is a beneficial physiologic response possible (such as
ngiogenesis, amelioration of heart failure, or modification
f genetic defects)? And, can similar results be achieved in
arger animals?
rotein and drug delivery. The rationale for using
TMD for drug and protein delivery is based on the need
or organ-specific pharmacotherapy. It is likely that many
otent drugs with severe adverse effects may be used more
eneficially if local concentrations could be increased while
eeping systemic concentrations low. For example, this
ould be of great advantage in angiogenesis therapy for
schemic myocardium. A handful of studies have examined
he potential of UTMD for such applications. Vascular
ndothelial growth factor (VEGF) bound to albumin mi-
robubbles was delivered to the heart using UTMD. A
3-fold augmentation of cardiac VEGF uptake was seen
ompared with systemic VEGF administration (16). A
tudy using lipid microbubbles with luciferase protein dem-
nstrated a six- to seven-fold augmented cardiac uptake of
uciferase compared with systemic administration (23). In
itro studies have shown that ultrasound contrast agents can
lso be used to deliver an antibiotic (25) or a radionuclide
56).
irect therapeutic effects of microbubble destruction.
he mechanical effect of microbubble destruction has been
romoted as potentially therapeutic, even without delivering
bioactive substance. Studies have shown that UTMD can
echanically declot thrombosed dialysis grafts in dogs
57,58). Microbubbles were able to further enhance throm-
olysis in combination with a thrombolytic drug such as
rokinase (59,60) or tissue plasminogen activator (61).
It has been suggested that UTMD in skeletal muscle can
nduce arteriogenesis and could therefore potentially be used
or treatment of peripheral ischemia (62). In general, these
pplications of UTMD use higher energies of ultrasound
han those used for diagnostic procedures or for typical
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February 1, 2005:329–35 Gene Therapy Using Contrast Echocardiographyubble destruction for delivery of substances. Careful eval-
ation of potential tissue damage with these approaches will
e required.
DVERSE EFFECTS
f the destruction of microbubbles is able to create pores in cell
embranes and deliver substances into tissues and cells, it is
lso possible to create cell and tissue damage that might
utweigh the benefits of this technique. Many studies have
een performed to investigate the risks of UTMD. The most
ommon finding was capillary rupture and hemorrhage or dye
xtravasation (7,45,63,64). However, most of these studies
ere performed ex vivo, with bolus injections of microbubbles
r with microbubble concentrations far higher than those used
linically. Other studies have not seen relevant adverse effects
uring in vivo applications of UTMD when using continuous
icrobubble infusions (65–67). It appears that the risks with
his technique will be closely related to the concentration of the
ltrasound contrast agent, the duration of the ultrasound
pplication, and the ultrasound pressure amplitude in the
issue. It is not clear whether underlying disease processes
ight render specific tissues or organs more susceptible to the
ioeffects of UTMD. It is likely that careful titration of all
hese factors will be necessary to keep the potential adverse
ffects low and have a maximum therapeutic benefit. However,
urther investigation, especially in larger animal models, is
eeded.
UMMARY AND OUTLOOK
herapeutic use of ultrasound contrast agents is an emerg-
ng technique with potential for a variety of targets. The
ost widely used application is directing gene expression to
ltrasound-accessible organs. The method of UTMD has
roven to be feasible for transport and delivery of plasmid
NA. It combines many favorable characteristics for gene
herapy, including minimal invasiveness, organ specificity,
ow toxicity, no immunogenicity, repeatable applicability,
nd low costs. However, the limiting aspect remains poor
fficiency. There has been inadequate quantitation of effi-
iency in many proof-of-principle studies, and it remains
nknown how the results in rodent experiments will apply
o larger animals. It does appear that technical improve-
ents are necessary to achieve clinically relevant therapeutic
fficiency. Despite this limitation, the potential of this
echnique is high, because there is still room for substantial
ptimization of microbubble composition (for maximal
ransport capacity of a given substance) and ultrasound
pplication (such as a three-dimensional ultrasound field,
hich can transfect a whole organ instead of a slice).
reater collaboration among membrane chemists, ultra-
ound engineers, and biologists is required for further
rogress. Besides the options in gene therapy, drug and
rotein delivery as well as direct mechanical effects of
icrobubble destruction have exciting potential for future
1pplications. Here again, efficiency will have to be improved
nd optimized.
onclusions. Ultrasound contrast agents may become an
mportant therapeutic tool for targeted treatments. This
pplication has grown out of contrast echocardiography and,
t least in the first studies discussed here, shows great
romise for cardiovascular applications.
eprint requests and correspondence: Dr. Paul A. Grayburn,
aylor Heart and Vascular Institute, 621 N. Hall Street, Suite
030, Dallas, Texas 75226. E-mail: paulgr@baylorhealth.edu.
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